SCHEMBL29558136

SCHEMBL29558136

CNC(=O)c1cc2c(Oc3ccc(N)cc3)ccnc2cc1OC

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 4/20 0.65
KDR P35968 10/20 0.62
MET P08581 4/20 0.62
AURKB Q96GD4 3/20 0.62
AURKA O14965 2/20 0.62
TEK Q02763 2/20 0.62
LCK P06239 1/20 0.62
PDGFRA P16234 5/20 0.55
RET P07949 4/20 0.54
FGFR2 P21802 3/20 0.53
FGFR1 P11362 2/20 0.53
FLT1 P17948 2/20 0.53
FLT4 P35916 2/20 0.53
PDXK O00764 1/20 0.53
RIPK2 O43353 1/20 0.53
LYN P07948 1/20 0.53
PDGFRB P09619 1/20 0.53
FGFR3 P22607 1/20 0.53
DDR1 Q08345 1/20 0.53
DDR2 Q16832 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1890635 1.00 AXL (0.65) AXLKDRMETAURKBAURKA
SCHEMBL23982910 0.90 KDR (0.54) AXLKDRMETAURKBAURKA
SCHEMBL22106609 0.89 AXL (0.70) AXLKDRMETAURKBAURKA
SCHEMBL1890374 0.89 AXL (0.63) AXLKDRMETAURKBAURKA
SCHEMBL29073385 0.88 AXL (0.59) AXLKDRMETAURKBAURKA
SCHEMBL12663554 0.88 AXL (0.60) AXLKDRMETAURKBAURKA
SCHEMBL1890626 0.87 KDR (0.70) AXLKDRMETAURKBAURKA
SCHEMBL12501921 0.87 AXL (0.62) AXLKDRMETAURKBAURKA
SCHEMBL22505692 0.86 KDR (0.60) AXLKDRMETAURKBAURKA
SCHEMBL1132598 0.86 AXL (0.62) AXLKDRMETAURKBAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4452947-A1 CRYSTALLINE FORMS AND SALT FORMS OF A KINASE INHIBITOR Exelixis, Inc. (US) 2024-10-30 EP disclosed
CN-118647603-A Crystalline forms and salt forms of kinase inhibitors 埃克塞里艾克西斯公司 2024-09-13 CN disclosed
EP-4426678-A1 COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS Exelixis, Inc. (US) 2024-09-11 EP disclosed
CN-118176182-A Compounds for the treatment of kinase dependent disorders 埃克塞里艾克西斯公司 2024-06-11 CN disclosed
CN-117820226-A Compounds for the treatment of kinase dependent disorders 埃克塞里艾克西斯公司 2024-04-05 CN disclosed
CN-117624045-A Compounds for the treatment of kinase dependent disorders 埃克塞里艾克西斯公司 2024-03-01 CN disclosed
CN-117603138-A Compounds for the treatment of kinase dependent disorders 埃克塞里艾克西斯公司 2024-02-27 CN disclosed
CN-117402114-A Compounds for the treatment of kinase dependent disorders 埃克塞里艾克西斯公司 2024-01-16 CN disclosed
CN-111757735-B Compounds for the treatment of kinase dependent disorders 埃克塞里艾克西斯公司 2023-09-22 CN disclosed
EP-4240333-A1 PHARMACEUTICAL COMPOSITIONS OF A KINASE INHIBITOR Exelixis, Inc. (US) 2023-09-13 EP disclosed
WO-2023122739-A1 CRYSTALLINE FORMS AND SALT FORMS OF A KINASE INHIBITOR EXELIXIS, INC. (US) 2023-06-29 WO disclosed
WO-2023081253-A1 COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS EXELIXIS, INC. (US) 2023-05-11 WO disclosed
EP-4143169-A1 PROCESSES FOR THE PREPARATION OF A KINASE INHIBITOR Exelixis, Inc. (US) 2023-03-08 EP disclosed
CN-115461328-A Process for preparing kinase inhibitors 埃克塞里艾克西斯公司 2022-12-09 CN disclosed
CN-114853746-A Formamide compound, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2022-08-05 CN disclosed
CN-114787144-A Pyridone compounds and methods for modulating protein kinases 埃克塞里艾克西斯公司 2022-07-22 CN disclosed
WO-2022098828-A1 PHARMACEUTICAL COMPOSITIONS OF A KINASE INHIBITOR EXELIXIS, INC. (US) 2022-05-12 WO disclosed